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Dr Nicholas G. Smedira (Cleveland, Ohio). I have no dis-
closures. Dr Schaff, as usual, your presentation was clear and
very informative, and I want to congratulate you on outstanding
results. My first question relates to whether we are underesti-
mating the prevalence of this disorder? We were taught 10
years ago that the incidence of obstruction in patients with hy-
pertrophic obstructive cardiomyopathy was around 25%. We
now know that with provocative maneuvers, it is as high as
75%. Are there more patients out there with this disorder
than we are appreciating?
The second question relates to midcavitary obstruction, which
you briefly described in the article. Do you require a specific640 The Journal of Thoracic and Cardiovascular Surggradient by your imaging study to identify those patients you would
operate on, or do all these patients have a resting gradient, and if there
is not a resting gradient, do you do provocative maneuvers, such as
amyl nitrate, as we do with standard outflow tract obstruction?
You briefly mentioned that 30% of the patients had a decrease in
functional status over 5 years, and in the article this was related to
atrial arrhythmias and right ventricular dysfunction. Therefore I
have a 2-part question. I have been very aggressive when treating
atrial arrhythmias in patients who have hypertrophic obstructive
cardiomyopathy. Are you more aggressive doing some ablative
procedure in this cohort of patients? If you see a patient who has
symptoms of right ventricular failure, would you now refer that pa-
tient directly to transplantation rather than the apical myectomy?
Thank you for this opportunity.
Dr Schaff. Your first question had to do with the prevalence of
ApHCM. In our institution this subtype accounts for approximately
8% of the patients who come through the HCM clinic. There might
be other patients with HCM and small cavities who might benefit
from enlarging their ventricles.
The second question had to do with midventricular obstruction.
It is important to recognize that you can access the midventricle
through the apex easily, and this should be considered if midven-
tricular obstruction remains after relief of subaortic obstruction.
The final question had to do with the development of atrial fibril-
lation, and we do combine maze procedures or pulmonary vein iso-
lation with subaortic myectomy in patients who have HCM and
troublesome atrial fibrillation. However, for patients who have
atrial arrhythmias but are not in continuous atrial fibrillation, we
are more conservative because prophylactic procedures can impair
atrial transport function.
Dr Smedira. What about the right ventricle, right ventricular
failure?
Dr Schaff. We do not have any special insights into indentifying
patients who might have right ventricular failure, and this is an
important issue.
Dr R. Duane Davis (Durham, NC). What do you think the true
incidence is? Do you use magnetic resonance at all for quantifica-
tion of and trying to determine where you think you will have
benefit?
Dr Schaff. Well, it is hard to knowwhat the true incidence is be-
yond the figures that I gave you. We do use cardiac magnetic res-
onance in these patients, but quantification of volumes is difficult
because of ventricular morphology. You can see the cavity quite
well, but most of the formulas to calculate ventricular volumes
are based on a ventricular shape that these patients do not possess.
It is important to develop or learn new methods for measuring ven-
tricular volume with magnetic resonance or other techniques be-
cause, in my view, that is the key to identifying the patients who
might benefit from this procedure.ery c March 2010
